Landmark trial
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
Pötter R, Tanderup K, Kirisits C, et al. · EMBRACE Collaborative Group / GEC-ESTRO GYN
DoseLab summary
The overview of the EMBRACE II study of image-guided IMRT with chemotherapy followed by MRI-based adaptive brachytherapy for locally advanced cervical cancer. It sets out the study's external beam dose constraints (hard and soft, with separate bowel limits when the para-aortic nodes are treated), the brachytherapy planning aims and limits for the high-risk CTV, GTV, point A, bladder, rectum, sigmoid and bowel in total EQD2, and the vaginal dose points. Open access.
Why this is useful
The source of the modern cervix brachytherapy planning aims (HR-CTV D90, bladder/rectum/sigmoid D2cc) and the EBRT soft constraints many centers use.
Reference details
- Title
- The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
- Authors / organization
- Pötter R, Tanderup K, Kirisits C, et al. · EMBRACE Collaborative Group / GEC-ESTRO GYN
- Publication / protocol
- Clin Transl Radiat Oncol. 2018;9:48–60
- Version
- Pending verification
- Year
- 2018
- DOI
- 10.1016/j.ctro.2018.01.001
- Disease sites
- GYN
- Topics
- Cervix, Brachytherapy, IGABT, EQD2, Dose Constraints, IMRT
- Fractionation context
- 45 Gy / 25 fx EBRT (nodal SIB) + image-guided brachytherapy; totals in EQD2
- Last reviewed by DoseLab
- 2026-09-30